US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Gene Editing

421.96

+5.361.29%

Number of Gainers:3

Number of Losers:1

Number of Flat:- -

PE:- -

High:427.81

Open:417.31

Low:417.31

Close:416.60

Volume:3.00M

Turnover:70.03M

Market Cap:9.52B

Float Cap:8.94B

Loading ...

Press Release: Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer

Editas Medicine Appoints Dan Ory, M.d., as Chief Medical Officer

THOMSON REUTERS

Beam Therapeutics’ BEAM-302 shows efficacy in Phase 1/2 AATD trial

Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of Beam-302 in Alpha-1 Antitrypsin Deficiency (Aatd) at the European Respiratory Society (Ers) Congress 2026

THOMSON REUTERS

Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026

Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Intellia Therapeutics (NTLA) and Ultragenyx Pharmaceutical (RARE)

Intellia Therapeutics Secures Major Non-Dilutive Loan Financing

Intellia Awards 163,100 RSUs to 41 New Employees Under Inducement Plan

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Intellia Therapeutics Secures $400 Million Senior Secured Term Loan Facility with OrbiMed

Intellia Therapeutics, - Additional $100 Mln Available Subject to Mutual Agreement During Five-Year Term

THOMSON REUTERS

CRISPR Therapeutics (CRSP) Extends CTX310 Durability, Is The Stock Still Cheap?

Simply Wall St.

Cathie Wood’s ARK Investment buys 96.2K shares of Intellia Therapeutics today

Investors Shrug Off Good News for Heart Patients from New Meds

Editas Medicine to Participate in Upcoming Investor Conferences

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigerfiesta.com/stock/BK4556/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4556","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4556\",,,,,undefined,":{"symbol":"BK4556","market":"US","secType":"PLATE","nameCN":"Gene Editing","latestPrice":421.96182,"timestamp":1789575957792,"preClose":416.5977,"halted":0,"volume":2995946,"delay":0,"changeRate":0.012876,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":5.364136,"latestTime":"09-16 12:25:58 EDT","open":417.31314,"high":427.8075,"low":417.31314,"amount":70025071.896295,"amplitude":0.025191,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1789588800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":2.636473,"peRate":-9.505067,"turnoverRate":0.00685,"increases":3,"decrements":1,"flats":0,"marketCap":9524729472,"floatMarketCap":8937821952},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4556\",,,,,undefined,":{"symbol":"BK4556","high":427.8075,"amplitude":0.025191,"preClose":416.5977,"low":417.31314,"pbRate":"2.636473","latestPrice":421.96182,"volume":2995945,"delay":0,"open":417.31314,"prevYearClose":431.70972,"prevWeekClose":422.4369,"prevMonthClose":478.4385,"prevQuarterClose":517.3469,"fiveDayClose":438.7054,"twentyDayClose":439.8328,"sixtyDayClose":511.9185,"secType":"PLATE","market":"US","turnoverRate":0.00685,"peRate":-9.505067,"marketCap":9524729472,"floatMarketCap":8937821952,"timestamp":1789575955733,"nameCN":"Gene Editing"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4556\",,,,undefined,":{"bkCode":"BK4556","up":3,"down":1,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4556\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2665732264","title":"Press Release: Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2665732264","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665732264?lang=en_us&edition=fundamental","pubTime":"2026-09-08 19:01","pubTimestamp":1788865260,"startTime":"0","endTime":"0","summary":"Experienced biotechnology executive with more than 25 years of leadership in cardiovascular and genetic medicine to lead clinical developmentAppointment strengthens executive leadership team as Editas","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASCI","BK4585","BK4588","GNMX","IE0031619046.USD","IE00B19Z4B17.USD","EDIT","BK4139","BK4214","AAP","BK4556","HELX","WDNA","IE00B7SZL793.SGD","IE00B66KJ199.SGD","SYNB","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665322562","title":"Editas Medicine Appoints Dan Ory, M.d., as Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2665322562","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665322562?lang=en_us&edition=fundamental","pubTime":"2026-09-08 19:00","pubTimestamp":1788865202,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nTUA8HHBTT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["EDIT","BK4139","BK4556"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665775321","title":"Beam Therapeutics’ BEAM-302 shows efficacy in Phase 1/2 AATD trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2665775321","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665775321?lang=en_us&edition=fundamental","pubTime":"2026-09-08 18:10","pubTimestamp":1788862245,"startTime":"0","endTime":"0","summary":"Beam Therapeutics (BEAM) announced updated clinical data from the Phase 1/2 trial evaluating BEAM-302 for alpha-1 antitrypsin deficiency, or AATD. ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/beam-therapeutics-beam-302-shows-efficacy-in-phase-1-2-aatd-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/beam-therapeutics-beam-302-shows-efficacy-in-phase-1-2-aatd-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1861558580.USD","BK4539","BK4588","BK4611","BK4139","BK4007","LU1861559042.SGD","BK4535","LENZ","BK4505","BK4585","BEAM","BK4556"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665290223","title":"Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of Beam-302 in Alpha-1 Antitrypsin Deficiency (Aatd) at the European Respiratory Society (Ers) Congress 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2665290223","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665290223?lang=en_us&edition=fundamental","pubTime":"2026-09-08 18:00","pubTimestamp":1788861601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nTUA4DNXZ2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BEAM","BK4585","LU1861558580.USD","BK4505","BK4611","BK4588","BK4535","LU1861559042.SGD","BK4139","BK4556"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665432460","title":"Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2665432460","media":"GlobeNewswire","labels":["conferences","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665432460?lang=en_us&edition=fundamental","pubTime":"2026-09-08 18:00","pubTimestamp":1788861600,"startTime":"0","endTime":"0","summary":"BEAM-302 Continues to Demonstrate Potential as One-time Treatment for Both Lung and Liver Manifestations of AATD, with AAT Protein Production Under Normal Physiological Control With Up to 18 Months Fo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/08/3357432/0/en/beam-therapeutics-presents-updated-clinical-data-from-the-phase-1-2-trial-of-beam-302-in-alpha-1-antitrypsin-deficiency-aatd-at-the-european-respiratory-society-ers-congress-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4007","EPV","BK4535","BK4505","LU1861559042.SGD","IDNA","BK4539","BK4556","BK4611","BK4139","LU1878469433.USD","ALT","BK4585","BEAM","PRTO","LU1861558580.USD","BK4599","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665317069","title":"Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Intellia Therapeutics (NTLA) and Ultragenyx Pharmaceutical (RARE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2665317069","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665317069?lang=en_us&edition=fundamental","pubTime":"2026-09-08 00:21","pubTimestamp":1788798066,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Merck & Company (MRK), Intellia Therapeutics (NTLA) and Ultrageny...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-merck-company-mrk-intellia-therapeutics-ntla-and-ultragenyx-pharmaceutical-rare-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-merck-company-mrk-intellia-therapeutics-ntla-and-ultragenyx-pharmaceutical-rare-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1023059063.AUD","LU1116320901.HKD","LU1699723380.USD","LU0006306889.USD","LU0320765646.SGD","SG9999015358.SGD","LU2324357040.USD","LU2361044949.HKD","BK4588","LU1917777945.USD","LU1093756325.SGD","LU0058720904.USD","BK4550","LU1069347547.HKD","VHT","LU0689626769.HKD","LU1983299246.USD","SG9999001176.SGD","LU1989771016.USD","SG9999002224.SGD","LU0265550946.USD","LU1066051498.USD","SG9999015341.SGD","PAWZ","LU0124676726.USD","LU2361044865.SGD","NTLA","LU2089984988.USD","LU1430594728.SGD","LU1061106388.HKD","LU0965509010.AUD","LU1934455194.USD","SG9999013999.USD","LU2125154935.USD","SGXZ57979304.SGD","TRUH","IE00BLSP4239.USD","IE00BLSP4452.SGD","LU0648001328.SGD","BK4556","LU0965508806.USD","SG9999014567.USD","BK4535","LU0106261372.USD","LU0861579265.USD","SG9999014559.SGD","LU0868494617.USD","LU1934455277.USD","LU0859254822.USD","BK4533","IE0002141913.USD","LU0868494708.USD","MRK","IE0009355771.USD","LU0477156953.USD","LU1116320737.USD","LU1934455863.HKD","LU2491049909.HKD","SG9999001440.SGD","LU2023250504.SGD","LU1057294990.SGD","LU0289739699.SGD","LU0208291251.USD","LU1989772840.SGD","SG9999014575.USD","LU1941712264.USD","FTXH","LU2361045086.USD","GDOC","LU2125154778.USD","IE00BFTCPJ56.SGD","LU1861558580.USD","LU0942090050.USD","IE00BJJMRZ35.SGD","LU1929549753.HKD","LU2491050154.USD","LU2112291526.USD","LU1066051811.HKD","LU1989772923.USD","LU1585245621.USD","SG9999001176.USD","FHLC","BMED","LU1066053197.SGD","LU2491050071.SGD","LU0203347892.USD","LU0823416689.USD","RXL","LU2357627491.SGD","LU0432979614.USD","LU0980610538.SGD","LU2125909593.SGD","BK4559","IE00B1BXHZ80.USD","LU1162221912.USD","IYH","LU2023250843.SGD","LU2461242641.AUD","PPH","RARE","JDOC","LU0098860793.USD","IE00B2B36J28.USD","LU2106854487.HKD","LU2433249047.HKD","LU0965509101.SGD","IHE","LU0122379950.USD","LU2360032135.SGD","LU1035773651.USD","LU0234572021.USD","LU0265550359.USD","IE00BSNM7G36.USD","LU0203345920.USD","LU1861559042.SGD","LU1974910355.USD","BK4007","LU0238689110.USD","LU0965509283.SGD","LU1066051225.USD","LU0320765489.SGD","LU1032466523.USD","BK4139","SG9999002232.USD","IE00B4R5TH58.HKD","LU0211331839.USD","LU1037948897.HKD","IE00BJT1NW94.SGD","LU1201861249.SGD","LU2468319806.SGD","LU0070302665.USD","SG9999014542.SGD","LU1571399168.USD","LU1291159041.SGD","LU1037948541.HKD","LU2125909247.SGD","IE00BN8TJ469.HKD","LU0130102774.USD","LU0266013472.USD","LU0985320562.USD","IXJ","LU1941712348.USD","BK4585","IE000M9KFDE8.USD","IE00BBT3K403.USD","LU1093756168.USD","HRTS","LU1923622614.USD","LU0130517989.USD","BK4534","BK4516"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665354991","title":"Intellia Therapeutics Secures Major Non-Dilutive Loan Financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2665354991","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665354991?lang=en_us&edition=fundamental","pubTime":"2026-09-05 05:36","pubTimestamp":1788557781,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics ( ($NTLA) ) has provided an announcement. On September 4, 2026, Intellia Therapeutics entered into a five-year non-dilutive s...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/intellia-therapeutics-secures-major-non-dilutive-loan-financing?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/intellia-therapeutics-secures-major-non-dilutive-loan-financing?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","NTLA","BK4588","BK4556","BK4139","LU1861558580.USD","LU1861559042.SGD","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665594033","title":"Intellia Awards 163,100 RSUs to 41 New Employees Under Inducement Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2665594033","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665594033?lang=en_us&edition=fundamental","pubTime":"2026-09-05 04:05","pubTimestamp":1788552311,"startTime":"0","endTime":"0","summary":"Intellia awards 163,100 RSUs to 41 new employees under inducement planIntellia Therapeutics awarded inducement grants to 41 new employees on Sept. 1, 2026, under its 2024 Inducement Plan.Grants cover ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260904:nNDLc0B329:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2W23.USD","BCDF","IE00BQXX3C00.GBP","BK4112","IE00BQXX3D17.EUR","LU1861558580.USD","BK4139","BK4535","IE00BGHQF748.EUR","BK4585","SG9999014013.SGD","BK4588","IE00B64PRP62.GBP","LU1861559042.SGD","LU2210149790.SGD","IE00BN0W2V16.EUR","LU2210150020.SGD","SG9999014005.SGD","SG9999014039.USD","SG9999014021.USD","IE00BN0W2T93.GBP","LU0314104364.USD","IE00B3QW5Z07.USD","BK4556","NDAQ","NTLA","IE00BKPKM429.USD","LU2095319765.USD","IE00BQXX3F31.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665135143","title":"Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2665135143","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665135143?lang=en_us&edition=fundamental","pubTime":"2026-09-05 04:05","pubTimestamp":1788552300,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., Sept.  04, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/04/3356788/0/en/intellia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","BK4588","LU1861559042.SGD","LCLG","BK4556","BK4139","BK4585","LU1861558580.USD","NTLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664344863","title":"Intellia Therapeutics Secures $400 Million Senior Secured Term Loan Facility with OrbiMed","url":"https://stock-news.laohu8.com/highlight/detail?id=2664344863","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664344863?lang=en_us&edition=fundamental","pubTime":"2026-09-04 20:50","pubTimestamp":1788526226,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics secures $400 million senior secured term loan facility with OrbiMedIntellia Therapeutics signed a USD 400 million non-dilutive senior secured term loan facility with OrbiMed.USD ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260904:nNDL5dLryB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2V16.EUR","SG9999014021.USD","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","LU2095319765.USD","BK4588","BK4535","NTLA","IE00BKPKM429.USD","BK4585","NDAQ","BK4112","IE00BQXX3F31.USD","IE00BQXX3D17.EUR","IE00BN0W2T93.GBP","IE00BGHQF748.EUR","LU1861558580.USD","IE00BQXX3C00.GBP","SG9999014013.SGD","LU1861559042.SGD","BK4139","LU0314104364.USD","SG9999014039.USD","SG9999014005.SGD","IE00BN0W2W23.USD","BCDF","LU2210149790.SGD","LU2210150020.SGD","BK4556"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664100334","title":"Intellia Therapeutics, - Additional $100 Mln Available Subject to Mutual Agreement During Five-Year Term","url":"https://stock-news.laohu8.com/highlight/detail?id=2664100334","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664100334?lang=en_us&edition=fundamental","pubTime":"2026-09-04 20:50","pubTimestamp":1788526209,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260904:nFWN44W0FQ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LU1861559042.SGD","NTLA","LU1861558580.USD","BK4585","BK4556","BK4535","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664826961","title":"CRISPR Therapeutics (CRSP) Extends CTX310 Durability, Is The Stock Still Cheap?","url":"https://stock-news.laohu8.com/highlight/detail?id=2664826961","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664826961?lang=en_us&edition=fundamental","pubTime":"2026-09-03 10:26","pubTimestamp":1788402388,"startTime":"0","endTime":"0","summary":"CRISPR Therapeutics (CRSP) is back in focus after new Phase 1a durability data for CTX310, its in vivo ANGPTL3 gene editing therapy, highlighted sustained lipid reductions one year after a single infusion.\nAt a share price of $56.92, CRISPR Therapeutics has had a mixed year, with a 30 day share price return of 14.83% and a year to date share price return of 5.86%, while the 1 year total shareholder return of 7.44% suggests that momentum has been improving recently as investors react to the...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crsp/crispr-therapeutics/news/crispr-therapeutics-crsp-extends-ctx310-durability-is-the-st","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crsp/crispr-therapeutics/news/crispr-therapeutics-crsp-extends-ctx310-durability-is-the-st","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4585","SYNB","LU1861559042.SGD","BK4556","DCF","BK4588","SPHQ","BK4611","LU1861558580.USD","ARKG","BK4139","CRSP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664847259","title":"Cathie Wood’s ARK Investment buys 96.2K shares of Intellia Therapeutics today","url":"https://stock-news.laohu8.com/highlight/detail?id=2664847259","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664847259?lang=en_us&edition=fundamental","pubTime":"2026-09-03 08:35","pubTimestamp":1788395714,"startTime":"0","endTime":"0","summary":"20:25 EDT Cathie Wood’s ARK Investment buys 96.2K shares of Intellia Therapeutics (NTLA) today Published first on TheFly – the ultimate source for ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cathie-woods-ark-investment-buys-96-2k-shares-of-intellia-therapeutics-today-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cathie-woods-ark-investment-buys-96-2k-shares-of-intellia-therapeutics-today-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NTLA","LU1861559042.SGD","LU1861558580.USD","SARK","BK4588","ARKW","ARKQ","ARKG","ARKX","ARKK","BK4556","BK4139","BK4544","ARKF","BK4585","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664866385","title":"Investors Shrug Off Good News for Heart Patients from New Meds","url":"https://stock-news.laohu8.com/highlight/detail?id=2664866385","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664866385?lang=en_us&edition=fundamental","pubTime":"2026-09-02 03:27","pubTimestamp":1788290820,"startTime":"0","endTime":"0","summary":"This year's run in drug stocks gained vigor from new treatments for heart attacks and strokes. Maybe some of those stocks are losing wind.At this past weekend's congress of the European Society of Car","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2089984988.USD","IE00BJT1NW94.SGD","LU2112291526.USD","LU1571399168.USD","BK4599","ISBC","LU0320765992.SGD","BK4581","CRSP","PJP","BK4588","BK4534","LU1983299246.USD","BK4211","IE0009355771.USD","IE00B2B36J28.USD","LU0868494617.USD","LU0109394709.USD","LU1061106388.HKD","BK4611","LU2468319806.SGD","AMGN","IE0002141913.USD","ARKG","IBBQ","IE00BJJMRZ35.SGD","BK4585","SG9999001440.SGD","LU0122379950.USD","PBE","BBH","LU0058720904.USD","BK4566","IE00B4R5TH58.HKD","LU0289739699.SGD","LU0889565916.HKD","TBXU","LU1861558580.USD","BK4533","LU2242652126.USD","LU1057294990.SGD","LU1861559042.SGD","BK4139","LU2242646821.SGD","IBB","IE00BFTCPJ56.SGD","BIB","LU1023059063.AUD","BK4556"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664851760","title":"Editas Medicine to Participate in Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2664851760","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664851760?lang=en_us&edition=fundamental","pubTime":"2026-09-01 21:00","pubTimestamp":1788267600,"startTime":"0","endTime":"0","summary":"ir@editasmed.com. media@editasmed.com","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/01/3354208/0/en/editas-medicine-to-participate-in-upcoming-investor-conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4556","BK4139","EDIT","SYNB"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":35,"code":"91000000","status":"200"}]}}